PT1611890E - Métodos para avaliação e tratamento do cancro - Google Patents

Métodos para avaliação e tratamento do cancro Download PDF

Info

Publication number
PT1611890E
PT1611890E PT05254157T PT05254157T PT1611890E PT 1611890 E PT1611890 E PT 1611890E PT 05254157 T PT05254157 T PT 05254157T PT 05254157 T PT05254157 T PT 05254157T PT 1611890 E PT1611890 E PT 1611890E
Authority
PT
Portugal
Prior art keywords
assessing
methods
treating cancer
cancer
treating
Prior art date
Application number
PT05254157T
Other languages
English (en)
Inventor
Mitch Raponi
Original Assignee
Veridex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex Llc filed Critical Veridex Llc
Publication of PT1611890E publication Critical patent/PT1611890E/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
PT05254157T 2004-07-01 2005-07-01 Métodos para avaliação e tratamento do cancro PT1611890E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/883,436 US20050003422A1 (en) 2003-07-01 2004-07-01 Methods for assessing and treating cancer

Publications (1)

Publication Number Publication Date
PT1611890E true PT1611890E (pt) 2009-09-29

Family

ID=35058443

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05254157T PT1611890E (pt) 2004-07-01 2005-07-01 Métodos para avaliação e tratamento do cancro

Country Status (14)

Country Link
US (1) US20050003422A1 (pt)
EP (1) EP1611890B1 (pt)
JP (1) JP2006014739A (pt)
KR (1) KR20060048684A (pt)
CN (1) CN1721553A (pt)
AR (1) AR049564A1 (pt)
AT (1) ATE440604T1 (pt)
AU (1) AU2005202520A1 (pt)
BR (1) BRPI0502433A (pt)
CA (1) CA2512493A1 (pt)
DE (1) DE602005016189D1 (pt)
DK (1) DK1611890T3 (pt)
MX (1) MXPA05007207A (pt)
PT (1) PT1611890E (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2504403A1 (en) * 2004-05-06 2005-11-06 Veridex, Llc Prognostic for hematological malignancy
US20080090242A1 (en) * 2006-09-29 2008-04-17 Schering Corporation Panel of biomarkers for prediction of fti efficacy
AU2008225130A1 (en) * 2007-03-12 2008-09-18 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
US8296867B2 (en) * 2008-03-21 2012-10-30 Bauer Hockey, Inc. Helmet for a hockey or lacrosse player
WO2010093465A1 (en) * 2009-02-11 2010-08-19 Caris Mpi, Inc. Molecular profiling of tumors
US11559540B2 (en) 2010-07-28 2023-01-24 Janssen Pharmaceutica Nv Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
CA2806112C (en) * 2010-07-28 2023-03-21 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
WO2017184968A1 (en) * 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019032489A1 (en) * 2017-08-07 2019-02-14 Kura Oncology, Inc. METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
US20210231666A1 (en) * 2018-06-06 2021-07-29 La Jolla Institute For Immunology Cd33 monocytes as a biomarker

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310687A (en) 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
US5221605A (en) 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
DE69620445T2 (de) 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
EP0946565B1 (en) 1996-12-20 2003-10-15 Tovarischestvo S Ogranichennoi Otvetstvennostju "Tabifarm" Method and device for production of lyophilized hydrochloride-1ss, 10ss-epoxy-13-dimethylamino-guaia-3(4)-en-6,12-olide
US6303654B1 (en) 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
AU3316600A (en) * 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
MXPA04004072A (es) * 2001-10-30 2004-09-06 Johnson & Johnson Metodos para valorar y tratar leucemia.
US7473526B2 (en) * 2002-03-29 2009-01-06 Veridex, Llc Breast cancer prognostic portfolio
US20030224422A1 (en) * 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
EP1502962A3 (en) * 2003-07-01 2006-01-11 Veridex, LLC Methods for assessing and treating cancer

Also Published As

Publication number Publication date
AU2005202520A1 (en) 2006-01-19
JP2006014739A (ja) 2006-01-19
BRPI0502433A (pt) 2006-04-04
DE602005016189D1 (de) 2009-10-08
KR20060048684A (ko) 2006-05-18
EP1611890B1 (en) 2009-08-26
CN1721553A (zh) 2006-01-18
US20050003422A1 (en) 2005-01-06
AR049564A1 (es) 2006-08-16
CA2512493A1 (en) 2006-01-01
EP1611890A1 (en) 2006-01-04
DK1611890T3 (da) 2009-11-16
MXPA05007207A (es) 2006-05-22
ATE440604T1 (de) 2009-09-15

Similar Documents

Publication Publication Date Title
PT1611890E (pt) Métodos para avaliação e tratamento do cancro
EP1732650A4 (en) COMPOSITION AND METHOD FOR CANCER TREATMENT
EP1945754A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER
HK1179275A1 (en) Compositions and methods for diagnosing and treating cancer
IL176919A0 (en) Methods and compositions for treating cancer
GB0822148D0 (en) Methods and apparatus
HK1077583A1 (en) Cudr as biomarker for cancer progression and therapeutic response
EP1755394A4 (en) METHOD OF TREATING CANCER
ZA200708575B (en) Methods and compositions for treating or preventing cancer
IL183059A0 (en) Cancer treatment method
EP1909854A4 (en) METHOD FOR TREATING CANCER
EP1855662A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
EP1951908A4 (en) METHODS RELATED TO DIAGNOSIS AND TREATMENT OF DEPRESSIONS
PT1830847E (pt) Tratamento para o cancro
IL179323A0 (en) Cancer treatment method
EP1977247A4 (en) METHODS OF DIAGNOSING AND TREATING PROSTATE CANCER
EP1804703A4 (en) CRYO-SURGICAL APPARATUS AND RELATED METHODS
IL179359A0 (en) Cancer treatment method
GB0403600D0 (en) Methods and reagents for treating disease
GB0428187D0 (en) Cancer treatment
EP1802617A4 (en) CANCER TREATMENT METHOD
EP2004219A4 (en) REAGENTS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER
GB0413346D0 (en) Treating cancer
GB0424552D0 (en) Methods and means
GB0426903D0 (en) Complexes and methods